The results showed active NLRP3 in the samples which was associated with caspase 1, IL-18 activity, disease severity and poor clinical outcomes (Rodrigues et al., 2020), suggesting that NLRP3 could serve as a therapeutic target for COVID-19. The gene discussed is NLRP3; the disease is COVID-19.